Jean-Christophe Tellier, UCB CEO
Quashing blockbuster hopes, FDA spurns UCB’s IL-17 drug for plaque psoriasis
After a months-long wait, UCB has finally heard back from the FDA regarding its plaque psoriasis drug. And the verdict is no.
The agency rejected …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
